Skip to content

US · HYPR · MEDICAL - DEVICES

Hyperfine, Inc. (HYPR) intrinsic value and stock valuation

$0.55as of 2026-11-21 · Mkt cap 82.53M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Hyperfine, Inc. DCF and intrinsic value

InvestorsCraft values HYPR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HYPR’s statements →

Hyperfine, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Guilford, CT 06437 hyperfinemri.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$13.6M+115.8% 5y CAGRd
20192025
Net income
-$-35.57M
20192025
Free cash flow
-$-29.13M
20192025
Total equity
$41M-9.4% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$13.6M$12.9M$11M$6.81M$1.5M
Operating income-$-37.09M-$-43.22M-$-48.12M-$-73.87M-$-64.87M
Net income-$-35.57M-$-40.72M-$-44.24M-$-73.16M-$-64.83M
EPSd-$-377.6K-$-562.35K-$-620.3K-$-1.04M-$-921.8K
Operating cash flow-$-27.95M-$-38.77M-$-41.81M-$-72.34M-$-47.18M
Capital expenditure-$-1.19M-$-380K-$-800K-$-580K-$-2.71M
Free cash flow-$-29.13M-$-39.15M-$-42.61M-$-72.92M-$-49.89M
Total assets$55.3M$58.9M$94.2M$134.1M$202.5M
Total debt$310K$270K$180K$0.00$0.00
Net debt-$-34.77M-$-37.38M-$-75M-$-118.24M-$-188.5M
Total equity$41M$49M$84.4M$123.7M$186.2M
Cash and short-term investments$35.1M$37.7M$75.2M$118.2M$188.5M
Income statement
20252024202320222021
Revenue$13.6M$12.9M$11M$6.81M$1.5M
Cost of revenue$6.81M$7M$6.28M$5.91M$2.66M
Gross profit$6.75M$5.89M$4.76M$910K-$-1.17M
Research and development expenses$17.5M$22.5M$22.5M$28.2M$25.8M
Selling, general and administrative expenses$26.4M$26.6M$30.4M$46.6M$37.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$43.8M$49.1M$52.9M$74.8M$63.7M
Cost and expenses$50.7M$56.1M$59.2M$80.7M$66.4M
Interest income$1.02M$2.49M$3.84M$760K$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.2M$1.01M$1.05M$1.01M$730K
Ebitda-$-33.37M-$-39.71M-$-43.18M-$-72.15M-$-64.12M
Operating income-$-37.09M-$-43.22M-$-48.12M-$-73.87M-$-64.87M
Total other income/expenses, net$1.51M$2.5M$3.88M$710K$20K
Income before tax-$-35.57M-$-40.72M-$-44.24M-$-73.16M-$-64.85M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-35.57M-$-40.72M-$-44.24M-$-73.16M-$-64.83M
Weighted average shares outstanding$94.2M$72.4M$71.3M$70.5M$70.3M
Weighted average diluted shares outstanding$94.2M$72.4M$71.3M$70.5M$70.3M
Balance sheet
20252024202320222021
Cash and short-term investments$35.1M$37.7M$75.2M$118.2M$188.5M
Net receivables$6.52M$8.3M$4.13M$3.13M$640K
Inventory$7.09M$5.83M$6.58M$4.62M$4.31M
Total current assets$50.9M$53.7M$88.9M$128.7M$197.5M
Property, plant and equipment, net$2.55M$3.12M$3M$3.25M$3.75M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$730K$820K$0.00$740K$0.00
Total non-current assets$4.35M$5.19M$5.29M$5.39M$4.99M
Total assets$55.3M$58.9M$94.2M$134.1M$202.5M
Accounts payable$4.05M$1.61M$1.21M$680K$2.25M
Short-term debt$250K$270K$180K$0.00$0.00
Deferred revenue$2.5M$1.49M$2.07M$1.38M$730K
Total current liabilities$11.7M$8.73M$8.77M$8.8M$15.7M
Long-term debt$70K$0.00$0.00$0.00$0.00
Deferred revenue, non-current$730K$1.05M$970K$1.53M$510K
Total non-current liabilities$2.52M$1.13M$1.03M$1.53M$510K
Capital lease obligations$310K$270K$180K$0.00$0.00
Total liabilities$14.3M$9.86M$9.8M$10.3M$16.3M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-330.02M-$-294.44M-$-253.72M-$-209.48M-$-136.32M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$41M$49M$84.4M$123.7M$186.2M
Total investments$730K$820K$0.00$740K$0.00
Total debt$310K$270K$180K$0.00$0.00
Net debt-$-34.77M-$-37.38M-$-75M-$-118.24M-$-188.5M
Cash flow statement
20252024202320222021
Net income-$-35.57M-$-40.72M-$-44.24M-$-73.16M-$-64.85M
Depreciation and amortization$1.09M$1.01M$1.05M$1.01M$730K
Stock-based compensation$2.8M$4.36M$4.74M$10.7M$6.9M
Change in working capital$4.41M-$-3.62M-$-3.62M-$-10.93M$8.97M
Accounts receivable$1.78M-$-2.77M-$-1.57M-$-1.55M$980K
Inventory-$-1.48M$560K-$-2.21M-$-310K-$-2.67M
Accounts payable$2.43M$380K$530K-$-1.57M$1.44M
Net cash provided by operating activities-$-27.95M-$-38.77M-$-41.81M-$-72.34M-$-47.18M
Investments in property, plant and equipment-$-1.19M-$-380K-$-800K-$-580K-$-2.71M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.19M-$-380K-$-800K-$-580K-$-2.71M
Common stock issued$27.5M$850K$170K$10K$1.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.5M$1.02M$170K$10K$176.8M
Net change in cash-$-1.63M-$-38.13M-$-42.44M-$-72.92M$126.9M
Cash at end of period$36M$37.7M$75.8M$118.2M$191.2M
Operating cash flow-$-27.95M-$-38.77M-$-41.81M-$-72.34M-$-47.18M
Capital expenditure-$-1.19M-$-380K-$-800K-$-580K-$-2.71M
Free cash flow-$-29.13M-$-39.15M-$-42.61M-$-72.92M-$-49.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Hyperfine, Inc.

        Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.

        CEO
        Maria Degois Sainz
        Employees
        102
        Beta
        1.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Hyperfine, Inc. (HYPR)?

        InvestorsCraft does not currently publish an intrinsic value for HYPR. How the IC value is calculated.

        Is HYPR undervalued?

        InvestorsCraft does not publish an undervaluation signal for HYPR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.